An in vitro study showed that the cytotoxicity of EGFR inhibitor tyrphostin AG1478 on breast cancer cell lines was enhanced when simultaneously suppressing the phosphoinositide 3‐kinase (PI3K) signaling pathway, aberrant activation and dysfunction of which were frequently reported in breast carcinogenesis (Li et al., 2012). This evidence concerns the gene EGFR and breast carcinoma.